Ally Bridge Group and Avidity Partners led a $101m Series B round in Endeavor BioMedicines, a clinical-stage biotechnology company, with participation from Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, Tekla Capital Management, T. Rowe Price Associates, Omega Funds and Longitude Capital. "Endeavor BioMedicines is developing precision medicines targeting the genetic culprits of cancer and fibrosis. Researchers have investigated Hedgehog and ULK1 signaling pathways over the last decade, but now we have the understanding and capability to identify the patients who will benefit most from them. The capital raised from a committed, top-tier investor syndicate enables us to deliver the right drug to the right patients in order to get the best clinical outcome," John Hood, Endeavor BioMedicines CEO and Chairman.